AstraZeneca PLC: * ASTRAZENECA PLC - IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER
* ASTRAZENECA - TRIAL MET PRIMARY ENDPOINT OF OVERALL SURVIVAL WITH A SINGLE PRIMING DOSE OF TREMELIMUMAB PLUS IMFINZI EVERY FOUR WEEKS VERSUS. SORAFENIB * ASTRAZENECA - IMFINZI MONOTHERAPY MET OVERALL SURVIVAL ENDPOINT OF NON-INFERIORITY VERSUS. SORAFENIB Source text for Eikon: Further company coverage:
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{Disclaimer}}
{{/Disclaimer}}